GSK feeds total scientific BS to Bloomberg to defend not floating ViiV!
“HIV drugs are proving to be so effective in containing the virus that GlaxoSmithKline Plc foresees a time, a decade away, when its most profitable business unit may no longer have a purpose” said David Redfern, Glaxo’s chief strategy officer and the chairman of its AIDS treatment unit ViiV Healthcare Ltd
This is such a load of BS and mutations say this is BS
This story is amazing, First GSK floats it will spin off ViiV and the shares go up, this is a fast growing business. Then it says it will NOT spin off ViiV and the shares fall 15%, now we get this ridiculous story.
Really? current treatments are good for all time? This is a planted story to say to “investors” “don’t worry you did not miss anything”
Professional punters on both sides of the Atlantic are still hooked on drugs. As artificial hips and knees maker Smith & Nephew crawled 11p higher to 1142p on prevailing hopes US rival Stryker could yet launch a £15-a-share cash offer, nosey buyers were sniffing around US biotech company Insmed amid rumours several major pharma groups have it at the top of their shopping list.
Shares in the New Jersey-based company traded $0.27 higher at $18.69 in early trade yesterday on talk of a possible cash offer north of $40 a share. Roche, Merck and the UK’s AstraZeneca, 8p off at 4423.5p, were all tipped as being interested and each one could buy Insmed with loose change.
Bid speculation intensified this week when Insmed shares experienced unusually high volume in one hectic session. More than 650,000 shares changed hands against a normal daily average of 400,000. It led leaders to surmise that a predator could be stakebuilding before launching a knock-out bid.
Read more: http://www.thisismoney.co.uk/money/markets/article-2979926/MARKET-REPORT-Footsie-climbs-professional-punters-sides-Atlantic-eye-pharma-opportunities.html#ixzz3TSYaaP64
Follow us: @MailOnline on Twitter | DailyMail on Facebook